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Hypothalamic hamartoma may present with epilepsy, specifically gelastic or dacrystic 
seizures, or endocrine dysfunction, commonly precocious puberty. The epilepsy in many is 
drug resistant, and has a high association with progressive cognitive, learning and 
behaviour difficulty. Medical treatment of seizures remains problematic, with many 
resistant to drug treatment. Surgical resection, or disconnection of the hamartoma  
provides the optimal chance of seizure control but with a realtively high risk of endocrine 
dysfunction the result of interference with the hypothalamic pituitary axis in many. 
Careful assessment and monitoring by specialist centres with discussion of optimal 






Hypothalamic hamartoma is a rare but now well recognised pathology causing drug 
resistant epilepsy, including the pathognomonic gelastic and dacrystic seizures, with 
marked cognitive and behaviour problems in many. Some however present primarily with 
precocious puberty, and seizures are not an obvious feature (although they may become 
evident in retrospect). Medical management is targeted at seizure control and/or delaying 
or monitoring precocious puberty and growth. In the absence of more conventional seizure 
types, the biggest challenge remains in diagnosing the seizures, which may remain 
unrecognised for some time: once diagnosed however, they remain resistant to 
antiepileptic medications  
 
Making an accurate diagnosis 
Accurate diagnosis poses challenges. Patients may be referred in one of two ways – to 
endocrinologists for investigation of precocious puberty, or alternatively to neurologists 
for evaluation of epileptic seizures. The pathognomonic seizure type, gelastic seizures, 
characterized by spontaneous mirthless laughter, often in isolation, are often missed at 
onset and may remain undiagnosed for some time. Older children and adults do not 
generally report a feeling of mirth; many report an unpleasant sensation or epigastric 
discomfort, or indeed a pressure to laugh. In its mildest form, patients may simply report 
an urge to laugh that can 
be suppressed.  In addition dacrystic, or ‘crying’ seizures may also be seen but again may 
go unrecognised.  It may only be with the manifestation of more typical epileptic seizures, 
such as evolution to convulsive seizures, that a diagnosis in retrospect may be made. 
Although seizures appear the most common presentation to neurology (61%) a significant 
proportion have (in some unrecognised) precocious puberty at presentation (66%) whilst 
  
25% present with evidence of both1. Age at presentation is wide; however early onset 
gelastic seizures in the first year of life are often missed or misdiagnosed as reflux or 
colic2. Further, a diagnosis of HH may be incorrectly suspected in individuals presenting 
with focal seizures where laughter is a component of the seizure, arising from the 
temporal or frontal regions. Also it may be suspected in children with more complex 
epilepsy with behavour difficulties where laughter may be a manifestation of limited 
ability in communication. In such cases HH should be excluded with high resolution 
magnetic resonance imaging but is rarely determined.  Where suspected, it must be 
ensured that an MRI with appropriate sequences has been performed to confirm or 
eliminate the diagnosis. This would require as a minimum a standard brain MRI protocol 
with contrast (no enhancement should be seen) including axial coronal T2, axial coronal 
and saggital T1 and a spin echo post contrast. Further volumetric  T1, volumetric  FLAIR 
(or thin T2/Flair sections if not available on scanner ) with volumetric sequences 
reformatted in 3 orthogonal planes ( axial,coronal and saggital)3. 
EEG is often normal at the outset, even if documented during a gelastic or dacrystic 
episode (Figure 1), so such investigational tests do not assist the diagnosis. That aside, 
EEG is recommended as subtle abnormalities may be apparent. Although not helpful in 
many with regard to diagnosis, the EEG may change over time4. Changes may herald the 
development of a greater impact in the individual, and consequently an epileptic 
encephalopathy with increasing cognitive and behavior difficulties. Consequently a sleep 
EEG may be more revealing than an EEG performed during events. Careful monitoring of 
the EEG to determine the emergence of abnormalities may aid in decision making with 
regard to management (see figure 2).  
In most patients with HH occurrence is sporadic. However about 5% have HH as part of 
Pallister Hall syndrome, seen in association with other anomalies such as post axial and 
central polydactyly, bifid epiglottis and imperforate anus5, an autosomal dominant 
condition caused by mutations in the GLI3 gene6. Further recent work has suggested that 
  
the sonic hedgehog (Shh) pathway is intimately involved, but not necessarily limited to a 
single gene. It appears that somatic mutations probably have an important role. A recently 
published study demonstrated somatic mutations in genes involving regulation of the Shh 
pathway in 14/38 individuals (37%) including GLI3, but also PRKACA, and brain tissue 
specific large copy number or loss of heterozygosity variants involving multiple Shh genes7.  
 
Initiation of treatment 
The evidence base for the optimal anticonvulsants to use in epilepsy associated with 
hypothalamic hamartoma, is limited. Most reports comment on medication failure and 
drug resistance with no particular useful therapy8. On assessment at diagnosis of gelastic 
seizures it is likely a usual protocol for focal seizures will be followed, such as 
carbamazepine or lamotrigine in the first instance. There is little evidence of response 
however. Anecdotal evidence suggests zonisamide may be of some benefit. However it 
also has to be considered that many series are reported from surgical centres and 
therefore likely to have a bias toward a drug resistant group. There is no question there 
appears to be a degree of variability in the clinical course, and not all inevitably 
demonstrate an evolution to marked behaviour and cognitive difficulty, remaining with 
gelastic seizures alone for many years9.  In others where precocious puberty has been the 
prominent presentation, seizures may be entirely absent, diagnosed in retrospect, or 
where they do occur follow a relatively benign course responding to a variety of different 
medications10.  However, individual risk benefit may need to be considered in each case, 
the aims of treatment being to minimise progression to convulsive seizures rather than 
reducing gelastic or dacrystic seizures per se, which do not alone appear detrimental to 
learning. We have no data as to whether medication makes any difference to the natural 
history of the condition, or on any longer term benefit. In the presence of convulsive 
  
seizures treatment is probably justifed, but in the presence of gelastic or dacrystic 
seizures alone, the data favouring medical therapy remain limited. 
 
Why are seizures so drug resistant? 
The results of EEG recordings from within the hamartoma, and indeed data from surgical 
series, demonstrate that the epileptic activity originates from within the hamartoma11;12. 
One might speculate that routine anti epileptic medications would poorly penetrate into 
such a lesion, and hence the poor response of localised gelastic and dacrystic seizures. 
However, studies of epileptogenesis of tissue from within such lesions suggest that the 
available antiepileptic agents have a mode of action irrelevant to these lesions. GABAA 
receptor mediated activation of L-type calcium channels induce neuronal excitation in 
excised tissue in vitro13, and blockade of these channels utilising nifedipine modulates the 
pathogenic high frequency oscillations in hypothalamic epileptogenic tissue; however this 
has not yet translated to clinical practice14 and the role of the newer agents remains 
untested.  
In a significant proportion of children presenting with gelastic seizures, progression is seen 
over time with the development of other seizure types, increasing cognitive and behaviour 
difficulties with more evident and/or widespread changes on EEG suggestive of a more 
widespread encephalopathy. Management should be targeted at preventing such an 
evolution, with post surgical studies demonstrating a degree of resolution in some cases15. 
The ketogenic diet, a high fat, low carbohydrate, low protein diet, has been used in 
refractory epilepsy in children for many years. It has been demonstrated to be of benefit 
in a randomised controlled trial of children with refractory epilepsy of many different 
types as compared to no change in treatment16. It has also been demonstrated to be of 
particular benefit in children with epilepsy resulting from malformations of cortical 
development17. One publication reports on the use of the ketogenic diet in children with 
  
epilepsy associated with hypothalamic hamartoma; 10/220 children were retrospectively 
determined to have been treated, with outcome data available in 6. These had been 
commenced on the diet at a mean age of 12 years, for a median duration of 9 months, 
although one child who particularly benefitted, continued for 14 years18.  Four had a 50-
90% reduction in multiple seizure types, including gelastic, focal and atonic seizures, and 
two failed to respond.  Possible mechanisms of action were studied utilising 
microelectrode recordings of small neurons in HH slices; decreased spontaneous firing was 
seen on exposure to ketone bodies, suggesting a possible benefit in this population. 
 
Beyond the seizures – optimising management 
Seizures of course do not present the only aspect of medical management for these 
children. Many will have subtle, subclinical and undiagnosed endocrine dysfunction, 
mainly disturbance of growth and puberty, and should be referred for a full dynamic 
assessment of pituitary function and subsequent longitudinal review even in the absence 
of overt clinical features.  
Hypothalamus-pituitary dysfunction classically  includes: a) central premature / 
precocious activation of the gonadotropin axis and puberty, b) a reduced growth velocity 
in relation to that child's height trajectory and advanced skeletal and sexual maturation, 
c) secondary (TSH deficiency) or tertiary (TRH deficiency) hypothyroidism and d) weight 
gain with eventual obesity and the secondary complications of the metabolic syndrome; f) 
life threatening ACTH deficiency which would predispose children to addisonian crises, 
and g) central diabetes insipidus are fortunately rare at presentation. It is however 
noteworthy that diabetes insipidus almost exclusively occurs in the context of surgical 
intervention to control seizures, including attempts at hypothalamic disconnection and 
gamma knife and can, perioperatively, cause severe crises in salt and water balance which 
in themselves can  impair consciousness or aggravate seizures. These data need confirming 
  
in wider data sets which systematically and longitudinally evaluate all children who 
present with HH from diagnosis, regardless of their presentation (neurological or 
endocrine) or treatment (medical and/or surgical).   
The risk of progressive cognitive and behavioural problems remains high, particularly 
where there is escalation of seizure frequency and multiple seizure types. Careful 
neuropsychological assessment, with regular review and educational support/liaison, 
before and after each major treatment change/intervention, will optimise the input 
provided to the individual and help determine the benefit or, by contrast, the detrimental 
contribution of each therapeutic modality to the eventual neuroendocrine outcome. 
Further behavioural assessment with psychiatric input where required is likely to be of 
help to families and schools. In such circumstances where behaviour is of concern , there 
should be early referral for consideration of surgery. 
 
Guidelines on management 
A high degree of suspicion is required to ensure appropriate imaging and consequently 
reach a diagnosis of epilepsy associated with hypothalamic hamartoma. On diagnosis 
however, although antiepileptic medication should be initiated, referral to a specialist 
surgical centre should be facilitated so careful followup and appropriate medical/surgical 
decisions are made. Recognising the lack of response of gelastic/dacrystic seizures to 
antiepileptic medication, it is not unreasonable to consider holding off medication at this 
stage. However full endocrine review should be undertaken. Careful regular evaluation 
should be ensured, including EEG, and, dependent on the type of lesion and clinical 
manifestation consideration given to early resection or ablation. Antiepileptic medication 
should certainly be considered with presentation of other seizure types, although the risk 




What is foreseen in the future? 
What is clear on reviewing the literature to date is that many reported observational 
series have a particular bias according to the centre, especially surgical. In the absence of 
a comprehensive HH registry of all children, what is difficult to determine is the true 
prevalence and range of neuro-endocrine presentations, and the overall natural history of 
the condition with and without intervention, according to radiological features. Of 
importance is to define which children would benefit from early surgical intervention, and 
in whom it may be avoided dependent on the risk-benefit ratio. The exceptional rarity of 
the condition mandates a concerted multicentre and multi professional effort to develop 
medical protocols for investigation and assessment and a core data set for monitoring 
neuro developmental and endocrine outcomes in relation to therapy, with pathways in 




Children (and adults) presenting with epilepsy resulting from hypothalamic hamartoma 
continue to provide a management challenge. An accurate early diagnosis remains 
paramount, with recognition of gelastic seizures.. There probably is a role for an initial 
trial of antiepileptic drugs, selection based on protocols for focal seizures, although more 
data are required with regard to response, and calcium channel blockers deserve further 
randomised study. This is particularly relevant if other seizure types emerge. Careful 
followup and review is required, with monitoring of cognitive function and behaviour and 
school support, within a specialist unit to ensure optimal timing of consideration of 
surgical management. Routine endocrine assessment of the hypothalamopituitary axis and 
  
longitudinal review should be part of ongoing medical monitoring, as well as educational 
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Key points 
 Seizures in general resistant to medication 
 AEDs used as for focal seizures 
 In many treatment targeted at ongoing convulsive seizures rather than gelastic or 
dacrystic seziures 
 Risk of evolution with multiple seizure types, and significant cognitive and 
behavioural impairment, monitoring  
 Many will have at the very least subtle, subclinical and undiagnosed endocrine 
dysfunction and consequently all warrant review and assessment 
 Require early referral for surgical assessment 
  
Figure 1: EEG performed in an 8 year old boy who had onset of gelastic seizures in 
neonatal period diagnosed in retrospect; generalized tonic clonic seizures onset 
age 7 years controlled on antiepileptic medication. MRI demonstrated a well 
defined sessile hypothalamic hamartoma filling much of the third ventricle.  EEG 





Figure 2: EEG in a 3 year old boy with a history of gelastic seizures since 2 years of 
age. No other seizure types had emerged, but developmental delay was noted 
prior to the development of seizures. MRI demonstrates a moderate sized 
heterogeneous sessile mass centred in the region of the right mamilary body 
consistent with a hypothalamic hamartoma (C).  Sleep EEG recording (A) shows 
interictal discharges in the left temporal region and frontal polyspikes in sleep. 
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